CML AdvocatesNetwork

SATURDAY, DECEMBER 9, 2017

5:30PM-7:30PM

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
Saturday, December 9, 2017: 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Program: Oral and Poster Abstracts. Type: Poster Hematology Disease Topics & Pathways: Adult, apoptosis, antibodies, Biological, Diseases, Therapies, CML, Mechanisms, Technology and Procedures, epigenetics, Study Population, Clinically relevant, hematopoiesis, Myeloid Malignancies, flow cytometry, TKI, NGS, RNA sequencing, signal transduction

1581 Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

1582 ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

1583 Role of Signal Transducing Adaptor Protein (STAP) Family in Chronic Myelogenous Leukemia

1584 CXCL12-Expressing Bone Marrow Niches Differentially Regulate CML Compared to Normal Stem Cells

1585 Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment

1586 Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells

1587 Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

1588 Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors

632. Chronic Myeloid Leukemia: Therapy: Poster I

1589 An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

1590 Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy

1591 Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture

1592 *In Vitro* Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions

1593 Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

1594 Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience

1595 Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) – Evaluation of Pioglitazone in Treatment-Free Remission

1596 E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

1597 Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

1598 Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

1599 Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

1600 Long-Term Outcome in Children and Adolescents with Chronic Myeloid Leukemia in Chronic Phase Treated with High-Dose Imatinib. the Italian Experience

1601 Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

1602 Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

1603 Comparison of Molecular Responses between e14a2 and e13a2 *BCR-ABL1* Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

1604 First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study

1605 Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

1606 Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

1607 Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia

1608 RIZ1 Gene Promoter Methylation Increases with Progression of Chronic Myeloid Leukaemia to Advanced Phases

1609 Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)

1610 Xpert® BCR-ABL Ultra, a High Sensitivity Assay, Demonstrates a Limit of Detection Reaching MR4.5 and below

1611 Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)

1612 Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

1613 Dasatinib-Induced Lymphocyte Elevation and Imbalance of *T Cell Receptor V Beta* Gene Expression in Chronic Phase Chronic Myelogenous Leukemia Patients

1614 ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients

1615 Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

1616 Observational Study of CML Italian Patients Who Discontinued TKIs

1617 Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

1618 Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month *BCR-ABL1* Transcript Level

1619 Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

1620 Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

1621 Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

1622 Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

1623 Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia

1624 A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

1625 Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome - a Gimema CML WP Analysis

1626 Evaluation of an Automated Immunoassay for Quantification of Imatinib in Plasma

1627 Altered Expression of Pdgfrα and Its Downstream Signalling Components May be Causal in the Development of Imatinib Induced Thrombocytopenia in CML Patients Receiving Imatinib Treatment

1628 10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

1629 Identification of a ‘Safe Haven’ for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

CML AdvocatesNetwork

SUNDAY, DECEMBER 10, 2017

6:00 PM-8:00 PM

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II

Program: Oral and Poster Abstracts Type: Poster
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

2860 Telomerase Inhibition Impairs Self-Renewal of ß-Catenin Activated Myeloproliferative Neoplasm Progenitors, ***Wenxue Ma, MD, PhD***

2861 Splenic Red Pulp Macrophages Provide a Secondary Stem Cell Niche for Chronic Myeloid Leukemia Stem Cells, ***Elias D Bührer, MD***

2862 Bcr-Abl1 Kinase-Independent Upregulation of FcγRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis, ***Mirle Schemionek, PhD***

2863 IFN-α Upregulates the Expression of C/EBPβ and Induces Myeloid Differentiation and Exhaustion of $CD34^{+}$ CML Stem Cells, ***Asumi Yokota, PhD***

2864 Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia, ***Sukjoong Oh, MD, PhD***

2865 *Hoxa9* and *Hoxa10* Induce CML Myeloid Blast Crisis Development through Activation of *Myb*Expression, ***Bandana Ajay Vishwakarma, BSc, MSc, PhD***

2866 Association between 9p21 Chromosome Polymorphisms rs1333040 and rs7865618 and Chronic Myeloid Leukemia, ***Federica SORA, MDç***

2867 Standardization of Two Dpcr Platforms for Detection of BCR/ABL1 - Minimal Residual Disease (MRD) in Ph+ Chronic Myeloid Leukemia (CML), ***Carmen Fava, MD, PhD***

632. Chronic Myeloid Leukemia: Therapy: Poster II

Program: Oral and Poster Abstracts Type: Poster
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

2868 Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes
Ahmad Ghorab, MD, MSc

2869 Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis, ***Ahmad Ghorab, MD, MSc***

2870 *Imatinib Suspension and Validation Study: Results from the Isav Study at 62 Months*, ***Silvia Mori, PhD***

2871 Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors ***Remco J Molenaar***

2872 No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs), ***Lilian Iglesias***

2873 The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors
Sung-Eun Lee, MD

2874 Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience
Martin C. Müller, MD

2875 Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib, ***Ellen K Ritchie, MD***

2876 Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors, ***Qian Jiang, MD***

2877 Association of Tyrosine Kinase Inhibitors with Vascular Adverse Events: A Cohort Study Using Pooled Electronic Health Record, ***Olivia Copelan, BA***

2878 Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop, ***Timothy P. Hughes, MD***

2879 Delayed Expansion of Murine BCR-ABL1^{+} Leukemia By Genetic and Pharmacological Inhibition of NOX2, ***Anna Martner, PhD***[1]

2880 Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia, ***Ali Alahmari, MD***

2881 Management of Chronic Myeloid Leukemia (CML) during Pregnancy Among Patients (pts) Treated with a Tyrosine Kinase Inhibitor (TKI): A Single-Center Experience, ***Rita Assi, MD***

2882 Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia, ***Maliha Khan***

2883 The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript, ***Ka-Won Kang, MD***

2884 Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib, ***Laura Cesini***

2885 Impact of Tyrosine-Kinase Inhibitors (TKIs) on Primary Hemostasis – Evaluation of Effects *In Vitro*, ***Ralf Knoefler, MD***

2886 Disovery of Novel Mutations Exclusively Shared By Accelerated and Blast Crisis Phase CML Patients Using Whole Exome Sequencing:Implication in Hunt for Common Biomarker /Drug Target of CML Progression, ***Psmh Pakistan Society For Molecular and Clinical Hematology***

2887 Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry, ***Joanna Gora Tybor***

2888 Hepatitis B Virus Seropositivity in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors: Preliminary Results of a Single-Center Cross-Sectional Study, ***Nurgul Ozgur Yurttas, MD***

2889 Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia, ***Ester Pungolino***

2890 Assessment of Standardization and International Scale (IS) Alignment Efforts of BCR-ABL1 Testing By the Chinese CML Alliance in an International External Quality Assessment Program, ***Ya-Zhen Qin***

2891 Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients, ***Juan Manuel Alonso Dominguez, MD, PhD, MSc***

2892 The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia, ***Adam J Mead, MD, PhD***[12]

2893 Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML), ***Jorge E. Cortes, MD***[1]

2894 Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice, ***Jorge E. Cortes, MD***

2895 Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial, ***Jorge E. Cortes, MD***

2896 Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML), ***Jorge E. Cortes, MD***

2897 Treatment Characteristics and Deep Molecular Response in Chronic Phase – Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study, ***Jorge E. Cortes, MD***

2898 Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study, ***David Yeung, PhD, BSc, FRACP, FRCPA, MBBS***

2899 Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia, ***May Garrett***

2900 *Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line,* ***Franck Emmanuel Nicolini, MD, PhD***

2901 *Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML*
Franck Emmanuel Nicolini, MD, PhD

2902 Molecular Responses and Outcomes of Pediatric CML Treated with Front-Line Imatinib and a Comparison between Pediatric and Adult Cohorts, ***Hsi-Che Liu, MD***

2903 Results from the U.S. *Life after Stopping TKIs* (Last) Study ***Ehab Atallah, MD***

2904 Both $CD4^+CD25^+Foxp3^+$ Regulatory T Cells and $CD3^-CD56^+$ NK Cells Affect the Response of Newly Diagnosed Chronic Myeloid Leukemia Patients to Treatment with a Tyrosine Kinase Inhibitor ***Fumihito Tajima, MD***

2905 A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients ***Luigia Luciano, MD***[1]

2906 Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia ***Iman Aboudalle, MD***

2907 No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline ***Alexis Genthon***

CML AdvocatesNetwork

MONDAY, DECEMBER 11, 2017

7:00 AM-8:30 AM

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III

Program: Oral and Poster Abstracts Type: Poster
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

4170 Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML ***Bing Z Carter, PhD***

4171 Vitamin K3 (menadione) Induces Cytotoxicity in Chronic Myeloid Leukemia Stem Cells By Upregulating DYRK2 through the Inhibition of SIAH2 Ubiquitin Ligase ***Chun Shik Park, PhD***

4172 Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML, ***Preetesh Jain, MBBS, MD, DM, PhD***

4173 Loss of G0S2 in Kinase-Independent TKI Resistance and Blastic Transformation of CML ***Anna M. Eiring, PhD***

4174 Oncogenic Heterogeneous Nuclear Ribonucleoprotein D-like Promotes the Growth of Chronic Myeloid Leukemia Cells through Post-Transcriptional Regulation of Pre-B-Cell Leukemia Homeobox 1, ***Dehuan Ji***

4175 Tumor Suppressor, *NORE1A (RASSF5)*, Is an Icsbp-Dependent Inhibitor of Aberrant Stress Granulopoiesis, ***Olatundun Williams, MD***

4176 An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease, ***Filomena Daraio, PhD***

4177 Mir-424 and Mir-503 Regulates Cobll1 Expression during the CML Progression

Seung Hun Han, PhD

4178 Expression Levels of PD-1 on CD8+ T Cells in Chronic Myeloid Leukemia with and without *BCR-ABL1* kinase Mutation ***Min Young Lee, MD, PhD***